about
Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseasesHigh-density lipoprotein subfractions--what the clinicians need to knowProteome of endothelial cell-derived procoagulant microparticles.Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population.Emerging role of high density lipoproteins as a player in the immune system.Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal ModelsModified HDL: biological and physiopathological consequences.HDLs, immunity, and atherosclerosis.LOX-1, OxLDL, and atherosclerosisOmega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.Postprandial lipemia as a cardiometabolic risk factor.HDL: to treat or not to treat?HDL in innate and adaptive immunity.HDL in infectious diseases and sepsis.Statin intolerance: diagnosis and remedies.Apolipoprotein C-III: From Pathophysiology to Pharmacology.Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases.Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.Pitavastatin and HDL: Effects on plasma levels and function(s).Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells.Dual effect of hypochlorite in the modification of high density lipoproteins.PCSK9 inhibition in statin-intolerant HeFH patients: What's new?Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux.15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages.Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini.Oxidized LDL induce hsp70 expression in human smooth muscle cells.Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus.Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia.Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?Prevalence of classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia.Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells.Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey.The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.Strategies for the use of nonstatin therapies.Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
P50
Q26830278-E587201B-6002-4750-886C-AE12A2182502Q27028064-F3EE5074-51D9-4917-9DAA-2EEE23EFC81FQ33225051-7FBEBA16-32C1-44A9-8D7B-FE81D87186F1Q34162711-74D76ADA-145A-4346-9422-9E948EDDAFFDQ34202968-CA04F435-E24B-452E-8BFE-24772C4D84BDQ34536594-1BCD4019-4428-452C-B4E3-7B851FD40963Q35460381-6D576136-2B89-422D-8FCD-884C7CC06AA5Q36366126-D1E8B28E-1001-4AC7-9F1A-8EFE8C5C02F1Q36531314-9327948B-756F-41D0-B0F1-7582B6CD43A3Q37924543-9E247227-7A7C-4CFB-95E0-1EBF302118AAQ38128283-40EA830E-A776-4403-A24C-9B27116530BBQ38130025-DEFDF488-6BC5-4458-B067-93A10E0DD49AQ38199746-75525F7B-2851-4305-87EE-44DCF87F3A54Q38217089-EC36B63F-A636-4BAF-9DC6-B8A8A9C0B704Q38220759-4C27E523-373D-4B3C-BDB6-1057014A5535Q38293482-E42F464C-A080-4092-B8C3-495DAC211948Q38430744-37A8FA84-2A13-447D-8137-EB085D183352Q38598885-3732843F-DF55-4025-8BCE-84DBFA657D15Q38621266-A59DF7B3-4300-40C8-80EA-01077727C61AQ38753729-09209BC9-3F8B-4B9F-ADBD-F735939AF3ACQ38833866-0CDFF40C-EF0B-4CE7-8EEB-27D5EE88BCAAQ39215606-94ACA15E-E6D9-4B09-BAAD-AC0076C68E51Q39439474-2545F795-56DE-4B82-9617-4E1C13E93D02Q39624064-554D58FC-1CB6-42C7-81AD-A2CC5104A3CEQ39629287-0C8FD698-1F30-404B-A4DF-39B073FF3D07Q40114602-F3F97243-B662-4A09-9FC1-BA6636BE4911Q40128246-31C3E5F1-5CAD-4CF9-8742-617810ECECD9Q40285890-54B71961-EEED-41CB-BEB8-25247661EA89Q40746808-C0404BB4-8938-401C-95F1-279EC3B00876Q41294680-523AB461-7D59-4F13-B968-06E0963889D4Q41503652-6D2E0108-A93C-4534-A59A-1569B0F7E87FQ41921590-AE6752AE-AEDA-472C-A778-AA730AECAD0CQ44298792-17F79583-6D31-4AA7-8B8F-4C9317535AC1Q45873443-1D071374-FB58-4C95-91EC-D5A7DC46DFF3Q45905376-48346A72-5347-4782-A3BE-58FA97C10BF3Q46792302-A7997106-0F62-44A5-933A-C814C936AC84Q47295481-6F2C2FFE-0DD2-4467-A65B-807ED4F70443Q49993738-0DCE76F5-1655-4C8D-9CF6-346094D665F6Q50071701-F289FF7B-9604-47CF-BDAC-2B9E0C7C389AQ53981427-044BA2D8-D62E-4497-9B20-DB2FEC68F253
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angela Pirillo
@ast
Angela Pirillo
@en
Angela Pirillo
@es
type
label
Angela Pirillo
@ast
Angela Pirillo
@en
Angela Pirillo
@es
prefLabel
Angela Pirillo
@ast
Angela Pirillo
@en
Angela Pirillo
@es
P1053
C-4228-2014
P106
P1153
6602244245
P21
P31
P3829
P496
0000-0002-2948-6257